Cellectar Biosciences Secures Four Patents for Proprietary Drug Delivery Platform and Lead Drug

Cellectar Biosciences, a biopharmaceutical company, has announced that it has been granted four patents across Europe, Australia, and Canada. These patents cover Cellectar's proprietary Phospholipid Drug Conjugate (PDC) delivery platform and its lead drug in development, iopofosine I 131.

Advancing Cancer Treatment and Detection

The European Patent Office granted a patent application for "Ether Phospholipid Compounds for Treating Cancer and Imaging Detection of Cancer Stem Cells." This patent strengthens the potential of iopofosine I 131 for the treatment of various cancers, including gliomas, lung cancer, melanoma, and more. The focus of this application is on targeting cancer stem cells. Additionally, the patent extends the coverage of iopofosine I 131's applications to underserved pediatric diseases.

Targeting Circulating Tumor Cells

The Canadian Intellectual Property Office and the Australian Patent Office have both granted a patent for "Phospholipid Ether Analogs for the Identification and Isolation of Circulating Tumor Cells." This patent acknowledges the importance of targeting circulating tumor cells in the diagnosis and treatment of cancer.

Fractionated Dosing for Effective Cancer Treatment

The Australian Patent Office and the European Patent Office have granted a patent application number for "Fractionated Dosing Of A Phospholipid Ether Analog For The Treatment Of Cancer." This patent recognizes the value of fractionated dosing in optimizing the effectiveness of cancer treatment using phospholipid ether analogs.

Innovative Drug Vehicles for Cancer Treatment

The European Patent Office has also granted a patent number for "Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles." This patent highlights the potential of phospholipid ether analogs as innovative drug vehicles for targeting cancer cells.

These four patents are significant achievements for Cellectar Biosciences, further solidifying its position as a leader in the development of novel cancer treatments.